Clinical Trial Update: A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002) [Phase 3]

View source ↗

Summary

A Phase 3 study comparing T-Guard vs ruxolitinib for steroid-refractory acute graft-versus-host disease has been terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Jakafi (ruxolitinib)
• T-Guard

Snippet

Sponsor: Xenikos | Conditions: Steroid-Refractory Acute Graft Versus Host Disease | Phase 3 | Status: TERMINATED | Results posted: 2024-08-27